SCHEMBL19742636

SCHEMBL19742636

CN(CCNC(=O)O)c1ccc(N)cc1CS(C)(=O)=O

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP19A1 P11511 1/20 0.34
LMNA P02545 2/20 0.34
ACHE P22303 2/20 0.34
SLC22A2 O15244 1/20 0.34
SLC22A1 O15245 1/20 0.34
ALDH1A1 P00352 1/20 0.34
TSHR P16473 1/20 0.34
MAPK1 P28482 1/20 0.34
CYP2C19 P33261 1/20 0.34
BLM P54132 1/20 0.33
PMP22 Q01453 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.31
CYP2D6 P10635 1/20 0.31
MTNR1A P48039 4/20 0.31
MTNR1B P49286 4/20 0.31
HTT P42858 1/20 0.31
SMN1; SMN2 Q16637 1/20 0.31
PIK3CD O00329 1/20 0.30
CA1 P00915 1/20 0.30
CA2 P00918 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29352527 0.84 CKS1B (0.41) ALDH1A1HTTCA1CA2CA9
SCHEMBL19742683 0.84 CKS1B (0.41) ALDH1A1HTTCA1CA2CA9
SCHEMBL19742423 0.83 ALDH1A1 (0.48) CYP19A1ALDH1A1L3MBTL1HTT
SCHEMBL30279944 0.81 L3MBTL1 (0.35) CYP19A1L3MBTL1
SCHEMBL19742573 0.81 LMNA (0.33) LMNAACHESLC22A2SLC22A1ALDH1A1
SCHEMBL19742646 0.80 PPIB (0.39) CYP19A1LMNAACHEALDH1A1L3MBTL1
SCHEMBL19742689 0.78 CYP19A1 (0.33) CYP19A1ACHEL3MBTL1
SCHEMBL19742662 0.78 MTNR1A (0.38) TSHRL3MBTL1MTNR1AMTNR1BSMN1; SMN2
SCHEMBL19742811 0.76 CYP19A1 (0.32) CYP19A1ACHE
SCHEMBL19742536 0.76 EPHX2 (0.40) ALDH1A1TSHRCYP2C19L3MBTL1CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3474855-B1 CK2 INHIBITORS, COMPOSITIONS AND METHODS THEREOF POLARIS PHARMACEUTICALS INC (US) 2022-01-26 EP disclosed
EP-3474855-A1 CK2 INHIBITORS, COMPOSITIONS AND METHODS THEREOF Polaris Pharmaceuticals, Inc. (US) 2019-05-01 EP disclosed
US-10227344-B2 CK2 inhibitors, compositions and methods thereof POLARIS PHARMACEUTICALS, INC. (US) 2019-03-12 US disclosed
WO-2017223432-A1 CK2 INHIBITORS, COMPOSITIONS AND METHODS THEREOF POLARIS PHARMACEUTICALS (US) 2017-12-28 WO disclosed
US-20170369489-A1 CK2 INHIBITORS, COMPOSITIONS AND METHODS THEREOF POLARIS PHARMACEUTICALS 2017-12-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170369489-A1 CK2 INHIBITORS, COMPOSITIONS AND METHODS THEREOF CSNK1A1, CSNK2A1, CSNK2A3 CYP19A1 1135/4885LMNA 2774/4885ACHE 2707/4885
US-10227344-B2 CK2 inhibitors, compositions and methods thereof CSNK1A1, CSNK2A1, CSNK2A3 CYP19A1 1135/4885LMNA 2774/4885ACHE 2707/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.